The Discounted Cash Flow (DCF) valuation of Newron Pharmaceuticals SpA (NWRN.SW) is 25.48 CHF. With the latest stock price at 15.20 CHF, the upside of Newron Pharmaceuticals SpA based on DCF is 67.6%.
Based on the latest price of 15.20 CHF and our DCF valuation, Newron Pharmaceuticals SpA (NWRN.SW) is a buy. buying NWRN.SW stocks now will result in a potential gain of 67.6%.
| Range | Selected | |
| WACC / Discount Rate | 4.1% - 6.7% | 5.4% |
| Long-term Growth Rate | 0.0% - 1.0% | 0.5% |
| Fair Price | 18.77 - 39.87 | 25.48 |
| Upside | 23.5% - 162.3% | 67.6% |